BIOLIGHT Life Sciences Overview
Biolight is a publicly-traded company focused on the development and commercialization of companies and products which address unmet needs and various Ophthalmic conditions. Its current products and portfolio companies address various diseases including mainly dry eye syndrome and glaucoma. Its portfolio companies and products are providing better devices, diagnostics, and drugs. Its delivery and diagnostics platforms reduce patient non-compliance with drug therapy administration, improve efficacy and safety of treatment, and help to personalize the medications.
Latest News
growth-positive
BioLight teams with Tel Aviv's Ichilov Hospital
BioLight Life Sciences Ltd. has announced an agreement with Tel Aviv Sourasky Medical Center - Ichilov Hospital to find and develop new technologies in ophthalmology. Under the agreement, BioLight will have the right of first refusal for exclusive licenses on Ichilov Hospital developments. This agreement will enable BioLight to expand and diversify its product portfolio through early-stage investment and create synergies between its portfolio companies. The collaboration strengthens BioLights position as the leading company in Israel in ophthalmology.
Partners
growth-positive
ביולייט מגייסת נבדק ראשון בהודו לניסוי קליני לאבחון מחלות עיניים
Israeli company BioLight announced that its subsidiary DiagnosTear has recruited the first participant in a clinical trial in India. The trial is part of a commercial collaboration agreement with an international pharmaceutical company and the LV Prasad Eye Institute. DiagnosTear develops the TeaRx technology for diagnosing eye diseases by analyzing tear fluid composition and personalizing and monitoring treatment for dry eye syndrome. The clinical trial aims to evaluate the products capabilities in diagnosing and treating patients with dry eye syndrome and is expected to last up to 6 months with approximately 600 participants. The trial is led by Dr. Sai Bhaskar, a prominent researcher in innovative eye treatments.
Customers
growth-positive
BioLight invests in US peripheral vision home test co
BioLight Life Sciences Ltd. has signed an investment agreement with Peripherex Inc., a US company that develops solutions for diagnosis and monitoring of peripheral vision impairment. BioLight will invest up to $3 million in Peripherex, with the goal of bringing an innovative and cost-effective tool to prevent blindness in glaucoma patients. The investment is part of BioLights strategy to focus on companies close to commercial launch of products that combine digital health and ophthalmology.
Investment
Team Members
5
Web & Social Links
| Website | bio-light.co.il/ |
Locations
Kiryat Atidim, Tel Aviv-Yafo, Israel
Photos & Videos
No files yet
